Uroplasty Upgraded to “Neutral” by Zacks (UPI)
Uroplasty (NYSE:UPI) was upgraded by Zacks from an “underperform” rating to a “neutral” rating in a report issued on Wednesday, AnalystRatings.Net reports. The firm currently has a $3.30 price objective on the stock. Zacks‘ price objective would suggest a potential upside of 1.54% from the stock’s previous close.
Uroplasty (NYSE:UPI) traded up 3.08% on Wednesday, hitting $3.35. The stock had a trading volume of 1,860 shares. Uroplasty has a 52 week low of $1.69 and a 52 week high of $3.90. The stock has a 50-day moving average of $3.30 and a 200-day moving average of $2.55. The company’s market cap is $69.9 million.
Uroplasty, Inc is a medical device company that develops, manufactures and markets products for the treatment of voiding dysfunctions.
To view Zacks’ full report, visit www.zacks.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.